Rein Therapeutics Faces Nasdaq Delisting Notice Over Sub-$1.00 Bid Price
RNTX is trading near its 52-week low of $0.694 (13% above the low) on light trading volume (0.3× avg).
Summary
Rein Therapeutics received a Nasdaq delisting notice on August 21, 2026, after its stock closed below $1.00 for 30 consecutive trading days. The company has until February 17, 2027, to regain compliance.
Key Events · Legal and Risk Events · RNTX
-
Nasdaq Delisting Notice Received
On August 21, 2026, Rein Therapeutics received a delisting notice from Nasdaq after its closing bid price fell below $1.00 for 30 consecutive trading days, violating Listing Rule 5550(a)(1).
-
180-Day Compliance Window
The company has until February 17, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
-
Delisting Risk if Non-Compliant
If compliance is not regained within the initial 180-day period, Nasdaq will commence suspension and delisting procedures, though the company may be eligible for an additional compliance period subject to meeting other listing standards.
-
Context: Recent Positive Developments
The delisting notice follows the FDA's Fast Track designation for LTI-03 in IPF on August 20, 2026, and a Q2 2026 10-Q showing $43.6M in cash with runway into Q1 2028 — yet the stock remains below the $1.00 threshold.
Analysis · RNTX · Life Sciences
Nasdaq has formally notified Rein Therapeutics that its stock traded below the $1.00 minimum bid price for 30 consecutive trading days, triggering a delisting review. The company now has 180 days — until February 17, 2027 — to regain compliance by closing at or above $1.00 for 10 consecutive business days. Failure to do so would lead to suspension and delisting from the Nasdaq Capital Market, severely impairing liquidity and institutional access for shareholders. This comes despite a recent FDA Fast Track designation for LTI-03 and a cash runway extending into Q1 2028, underscoring that the market is pricing the stock below the exchange's minimum threshold.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNTX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.5M. The 52-week trading range was $0.69 to $2.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.